

# Diabetic Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DAB566DAF222EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: DAB566DAF222EN

## Abstracts

The 7 major diabetic macular edema market reached a value of US\$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 7.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.

The diabetic macular edema market has been comprehensively analyzed in IMARC's new report titled "Diabetic Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic macular edema refers to a condition in which the small blood vessels in the retina are damaged as a result of diabetes, leading to swelling or accumulation of fluid in the macular, it often develops gradually and may not cause noticeable symptoms in the early stages. As the disease progresses, individuals might experience blurring or distortion of central vision, difficulty seeing fine details, or changes in color perception. In some cases, they may also notice blind spots or dark spots in their vision. In advanced stages, vision might become increasingly impaired, making it difficult to read, drive, or carry out other daily activities. The ailment is diagnosed through a comprehensive eye exam by an ophthalmologist. During the examination, the eye doctor will perform a visual acuity test to determine the clarity of vision and a dilated eye exam to assess the retina and optic nerve. Several specialized tests, such as optical coherence tomography (OCT) and fluorescein angiography (FA), are also utilized to evaluate the severity as well as the extent of the ailment.

The increasing cases of high blood sugar levels in diabetic individuals, which damage the blood vessels in the retina, are primarily driving the diabetic macular edema market. In addition to this, the rising prevalence of several associated risk factors, including chronic inflammation, oxidative stress, accumulation of advanced glycation end

products (AEGF) drugs, such as ranibizumab, aflibercept, bevacizumab, etc., for reducing fluid leakage in the macular and improving vision is acting as another growth-inducing factor. Additionally, the inflating utilization of vitrectomy, a surgical procedure in which the vitreous gel in the eye is removed and replaced with a clear saline solution, to treat cases where there is significant bleeding in the eye is further augmenting the market growth. Apart from this, the emerging popularity of subthreshold micropulse laser therapy over traditional laser therapy on account of its several associated benefits, including lower risk of damage to the retina, reduced discomfort during treatment, shorter recovery time, etc., is expected to drive the diabetic macular edema market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic macular edema market in the United States, EU5 (Germany, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic macular edema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic macular edema market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the diabetic macular edema market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the diabetic macular edema market  
Reimbursement scenario in the market  
In-market and pipeline drugs

### Competitive Landscape:

This report also provides a detailed analysis of the current diabetic macular edema marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:  
Market Insights

How has the diabetic macular edema market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the diabetic macular edema market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the diabetic macular edema market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of diabetic macular edema across the seven major markets?

What is the number of prevalent cases (2018-2034) of diabetic macular edema by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of diabetic macular edema by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with diabetic macular edema across the seven major markets?

What is the size of the diabetic macular edema patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of diabetic macular edema?

What will be the growth rate of patients across the seven major markets?

### Diabetic Macular Edema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for diabetic macular edema drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic macular edema market?

What are the key regulatory events related to the diabetic macular edema market?

What is the structure of clinical trial landscape by status related to the diabetic macular edema market?

What is the structure of clinical trial landscape by phase related to the diabetic macular edema market?

What is the structure of clinical trial landscape by route of administration related to the diabetic macular edema market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 DIABETIC MACULAR EDEMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
- 4.5 Competitive Intelligence

### **5 DIABETIC MACULAR EDEMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 DIABETIC MACULAR EDEMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034?)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034?)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034?)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034?)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034?)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034?)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034?)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034?)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 DIABETIC MACULAR EDEMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 DIABETIC MACULAR EDEMA - UNMET NEEDS**

## **10 DIABETIC MACULAR EDEMA - KEY ENDPOINTS OF TREATMENT**

## **11 DIABETIC MACULAR EDEMA - MARKETED PRODUCTS**

- 11.1 List of Diabetic Macular Edema Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Ozurdex (Dexamethasone ophthalmic) - AbbVie
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Iluvien (Fluocinolone acetonide) - Alimera/EyePoint Pharmaceuticals
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Vabysmo (Faricimab) - Roche
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Lucentis (Ranibizumab) - Genentech/Novartis Ophthalmics
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Eylea (Aflibercept) - Bayer/Regeneron Pharmaceuticals/Sanofi
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 DIABETIC MACULAR EDEMA - PIPELINE DRUGS**

- 12.1 List of Diabetic Macular Edema Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 MYL1701P - Momenta Pharmaceuticals/Viatris
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 KSI 301 - Kodiak Sciences
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 APX3330 - Ocuphire Pharma
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 THR149 - Oxurion
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 EXN 407 - Exonate
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. DIABETIC MACULAR EDEMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. DIABETIC MACULAR EDEMA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 DIABETIC MACULAR EDEMA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Diabetic Macular Edema - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034?)

- 15.2.2 Diabetic Macular Edema - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034?)
- 15.3 Market Scenario - United States
  - 15.3.1 Diabetic Macular Edema - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034?)
  - 15.3.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.3.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Diabetic Macular Edema - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034?)
  - 15.4.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.4.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Diabetic Macular Edema - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034?)
  - 15.5.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.5.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Diabetic Macular Edema - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034?)
  - 15.6.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.6.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Diabetic Macular Edema - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034?)

- 15.7.2 Diabetic Macular Edema - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034?)
- 15.7.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Diabetic Macular Edema - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034?)
  - 15.8.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.8.3 Diabetic Macular Edema - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Diabetic Macular Edema - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034?)
  - 15.9.2 Diabetic Macular Edema - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.9.3 Diabetic Macular Edema - Access and Reimbursement Overview

## **16 DIABETIC MACULAR EDEMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 DIABETIC MACULAR EDEMA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 DIABETIC MACULAR EDEMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Diabetic Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DAB566DAF222EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DAB566DAF222EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

